Isotretinoin is commonly prescribed for the treatment of severe acne. Although cases of infl ammatory bowel disease (IBD) have been reported in isotretinoin users, a causal association remains unproven.
INTRODUCTION
Isotretinoin (Accutane, Amnesteem, Sotret, Claravis) is a vitamin A analog that was approved by the Food and Drug Administration for the indication of severe nodulocystic acne in 1982. Subsequent to its approval, isotretinoin has become a widely prescribed medication despite its well-known teratogenic eff ects ( 1 -4 ) . In the postmarketing period, several reports of patients developing infl ammatory bowel disease (IBD) aft er treatment with isotretinoin were published ( 5 -11 ) . IBD was subsequently listed in the package insert for Accutane as an adverse gastrointestinal eff ect ( 12 ) . In addition, the potential connection between isotretinoin and IBD has spurred a number of multimillion dollar lawsuits ( 13 ) . In June 2009, Roche Pharmaceuticals (Nutley, NJ) pulled Accutane from the US market in the face of competition from generic makers of isotretinoin, who now supply more than 95 % of the US market. Th e company also cited " high costs from personalinjury lawsuits " as a reason for withdrawal, although they dispute the validity of claims that isotretinoin is related to IBD ( 14 ) .
Evidence supporting a causal connection between isotretinoin and IBD largely consists of isolated case reports ( 5 -11 ) . In addition, an analysis of the Food and Drug Administration ' s MedWatch adverse event monitoring system between 1997 and 2002 showed 83 reported cases of de novo IBD developing in individuals exposed to isotretinoin ( 15 ) . An association between isotretinoin and IBD may be biologically plausible based on the pleotropic eff ects of isotretinoin on the innate and adaptive intestinal immunoregulatory capacity ( 16 ) . Nevertheless, although these case reports are certainly a cause for concern, they are insuffi cient evidence to determine whether isotretinoin users have a risk of IBD that exceeds the background rate ( 17 ) .
Isotretinoin Use and the Risk of Infl ammatory Bowel Disease: A Case -Control Study
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Total number of subjects in PharMetrics Patent-Centric Database at time of analysis n = 55,000,000
Controls with no claims for IBD, matched 3:1 to cases on the basis of age, gender, health plan, region, and length of enrollment n = 280,878
Matched controls with at least 12 months of continuous enrollment n = 21,832
Indeterminate IBD n = 97
Crohn's disease n = 3,664
Ulcerative colitis n = 4,428
All subjects with at least 1 diagnosis claim for UC (ICD-9 556) or CD (ICD-9 555) n = 93,639
All subjects meeting primary IBD definition (≥3 IBD diagnoses on separate dates or ≥1 IBD diagnosis and 1 IBD-specific medication) with at least 12 months of continuous enrollment prior to first IBD claim.
Specific diagnosis assigned based on majority of most recent 9 claims for UC or CD Figure 1 . Derivation of study population including subjects with infl ammatory bowel disease and matched controls. CD, Crohn ' s disease; IBD, infl ammatory bowel disease; ICD-9, International Classifi cation of Diseases, 9th Revision code; UC, ulcerative colitis.
To date, only a single case -control study performed in Manitoba has evaluated this topic and did not demonstrate an association between isotretinoin use and subsequent development of IBD ( 18 ) . However, this study did not include an analysis of temporality, dose -response, and other factors important in determining causality, and may have underestimated the eff ect size. To further evaluate the possibility of an association between isotretinoin and IBD, we performed a case -control study using a large US administrative claims database.
METHODS
Study design and data source
We conducted a case -control study using administrative claims data obtained from individuals captured within the PharMetrics Patient-Centric Database (IMS Health, Watertown, MA) from 1 January 2000 to 31 December 2005. Th is longitudinal, individual-level database includes 87 health plans across 33 states in the United States. At the time the data were extracted, the database contained information on 55 million Americans. Data elements used in this analysis included both in-patient and outpatient diagnoses (International Classifi cation of Diseases, 9th Revision, Clinical Modifi cation (ICD-9-CM) format), procedures (Current Procedural Terminology, 4th Edition (CPT-4)), retail and mail order prescription records (National Drug Code (NDC), generic name, dosage, and quantity dispensed), demographic information (year of birth, gender, US census region), health plan, as well as start and stop dates for plan enrollment and pharmacy benefi ts. Th is database has been used in other epidemiological studies of IBD ( 19 -24 ) , and has been reported to be representative of the commercially insured population in the United States ( 25 ) . Encrypted unique patient identifi ers were used to integrate pharmacy and medical claims and all analyses were based on de-identifi ed data. Th e study protocol was granted an exemption by the Institutional Review Board at the University of North Carolina because it involved the use of existing and de-identifi ed data.
Study population
Case ascertainment . All individuals with at least 12 months of continuous health plan enrollment were eligible for inclusion in this analysis. Cases of Crohn ' s disease (CD), ulcerative colitis (UC), and indeterminate IBD were identifi ed using a previously reported administrative defi nition ( 23 ) . Th is defi nition included subjects with at least three health-care contacts, on diff erent days, associated with an ICD-9-CM diagnosis code for CD (555.xx) or UC (556.xx), or subjects with at least one claim for CD or UC, and at least one pharmacy claim for any of the following medications: mesalamine, olsalazine, balsalazide, sulfasalazine, 6-mercaptopurine, azathioprine, infl iximab, adalimumab, and enteral budesonide. For subjects who had claims for both CD and UC, disease assignment was made according to the majority of the last nine claims (see Figure 1 ).
To measure isotretinoin exposure preceding the diagnosis of IBD, we required that cases have a minimum of 12 months of health
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plan enrollment before the fi rst IBD-related claim (i.e., 12 months without a diagnosis code for CD or UC, or a prescription for oral or rectal aminosalicylates, 6-mercaptopurine, azathioprine, methotrexate, infl iximab, or adalimumab). Isotretinoin exposure was measured during this 12-month period (exposure period).
Control ascertainment . For each case, we randomly selected up to three non-IBD controls without any claims for CD or UC over the duration of their health plan enrollment. Controls were matched to cases on the following factors: age (within 2 year increments), gender, US census region (east, south, midwest, and west), health plan, and length of enrollment (in 3 month increments).
Assessment of isotretinoin exposure
Th e number of isotretinoin prescriptions occurring in the 12 months before the fi rst diagnosis of CD or UC for cases, or in the fi rst 12 months of enrollment for controls was identifi ed using NDC codes for generic isotretinoin and the following trade names: Accutane, Claravis, Sotret, and Amnesteem. Both cases and controls had exposure status assessed over an equal time frame preceding ascertainment of incident disease status. In our primary analysis, we considered isotretinoin use as a dichotomous (ever / never) exposure. We subsequently performed a number of subanalyses examining dosage and length of treatment, including (i) maximum daily dose of isotretinoin, (ii) any dose escalation during therapy, and (iii) sum of the number of days supplied for all prescriptions. Daily dose was calculated as: (quantity / days supplied) × strength.
Secondary analyses
As the diagnosis of IBD can be delayed, and because of wide variation in latency time between isotretinoin exposure and the development of IBD in published case reports, we repeated our analysis requiring a longer exposure period (24 months before the fi rst IBD diagnosis or IBD-related prescription for cases, 24 months of continuous enrollment for controls).
To minimize the possibility of misclassifying subjects with selflimited colitis, ischemic colitis, or other non-IBD conditions as IBD cases, we repeated our analyses using a more stringent case defi nition (more than fi ve claims for CD or UC, occurring on separate days).
Isotretinoin is primarily prescribed among younger age groups for the treatment of acne ( 26, 27 ) , whereas IBD can aff ect individuals of all ages ( 28 ) . Owing to this discrepancy, we performed an additional subanalysis restricted to individual subjects between the ages of 12 and 45 years, the peak age range of isotretinoin users ( 1 ).
Isotretinoin is occasionally prescribed for the treatment of nonacne dermatological disorders. Some of these conditions (such as pyoderma faciale, pyodermatitis-pyostomatitis vegetans, and hydradenitis suppurativa) are known extraintestinal manifestations of IBD that may precede its diagnosis ( 11, 29, 30 ) . To minimize the possibility that isotretinoin use for such conditions were biasing our results (i.e., that subclinical onset of IBD preceded isotretinoin exposure in some exposed cases), we performed an additional analysis restricting the exposure to only those with a coded diagnosis of acne vulgaris (ICD-9 code 760.1) on the same date or before a fi rst prescription of isotretinoin.
In addition, to test whether the relationship between isotretinoin and IBD was confounded by acne, we evaluated whether acne was independently associated with IBD by logistic regression modeling.
Sensitivity analysis
Owing to heightened awareness of teratogenicity and the associated rigorous Food and Drug Administration-required safety monitoring ( 31 ) , individuals taking isotretinoin are more likely to be scrutinized by a physician than their same-age peers. Th is is particularly true for adolescents, who generally have low healthcare utilization in the United States ( 32 ) . It is possible that this might lead to diff erential outcome misclassifi cation (i.e., higher sensitivity of IBD diagnosis among exposed individuals). To evaluate the potential impact of diff erential outcome misclassifi cation in isotretinoin exposed and unexposed individuals, we performed a sensitivity analysis varying the rate of detection in the unexposed group from 50 to 99 % , while keeping the sensitivity of the exposed group at 100 % . Previously reported equations for calculating expected results were used for this analysis ( 33 ) .
Statistical analysis
Bivariate analyses for each non-matching variable were performed with Pearson ' s χ 2 tests to compare distributions between cases and controls. To estimate the association between exposure to isotretinoin and a diagnosis of IBD, all odds ratio (OR) estimates were obtained from conditional logistic regression to account for the matching strata of age (within 2 years), gender, geographic region, health plan, and duration of enrollment (within 3 months). All statistical analyses were performed using STATA version 10.0 (StataCorp or Stata Corporation, College Station, TX).
RESULTS
Characteristics of study population
Our study population comprised 8,189 cases (3,664 CD, 4,428 UC, and 97 IBD unspecifi ed) and 21,832 controls. Women comprised 56 % of the study population. As sex, age, and geographic region were matched by design, distribution of these variables in cases and controls was the same. Isotretinoin use during the 12-month exposure period occurred in 60 individuals (24 cases and 36 controls). Cases and controls had similar rates of acne (3 and 2 % , respectively). Among those who were exposed to isotretinoin, 54 of 60 (90 % ) had a diagnosis of acne vulgaris on the same date or preceding the prescription date ( Table 1 ) . Th ere were no missing data for the exposure or outcome, or for the other covariates including age, gender, geographic region, acne diagnosis, or disease manifestation.
Results of matched analyses
Th e OR for IBD in relation to any isotretinoin use was 1.68 (95 % confi dence interval (95 % CI): 0.98, 2.86) ( 
Effect of maximum daily dose, dose escalation, and duration of therapy
Apart from analyzing isotretinoin exposure as a binary variable, further exposure analysis was performed using information on dosage and duration of isotretinoin treatment. As isotretinoin is prescribed at a range of doses, we fi rst assessed the eff ect of the maximum daily dose. Compared with non-users, the OR for UC for each 10 mg increase in the daily dose of isotretinoin was 1.23 (95 % CI: 1.04, 1.45), whereas for each 20 mg increase in the daily dose, the OR was 1.50 (95 % CI: 1.08, 2.09). We further analyzed whether dose escalation aff ected risk of UC. Compared with unexposed subjects, the OR for those who had their dose of isotretinoin increased at some point during the course of therapy was 15.00 (95 % CI: 1.75, 128.39), whereas the OR for those who remained on a stable dose was 2.03 (95 % CI: 0.61, 6.74). Next, we examined the eff ect of duration of therapy on the risk of UC. Compared with unexposed individuals, the OR for those taking isotretinoin for at least 60 days was 5.63 (95 % CI: 2.10, 15.03), whereas the OR for those taking isotretinoin for < 2 months was 2.50 (95 % CI: 0.61, 10.23). As shown in Table 3 , the direction of the eff ects of maximum daily dose, dose escalation, and duration of therapy were not observed in CD.
Secondary analyses
Aft er increasing the length of the required exposure period to at least 24 months, isotretinoin was associated with a smaller but signifi cantly increased risk of UC (OR 2.90, 95 % CI: 1.17, 7.20) but not CD (OR 0.89, 95 % CI: 0.32, 2.52). Results of the age-restricted analysis (12 -45 years of age) were similar to those obtained from the full study population (OR for IBD, UC, and CD of 1.55, 4.90, and 0.57, respectively). Similarly, changing to a more stringent outcome defi nition requiring fi ve or more claims for CD or UC (in an eff ort to eliminate cases of self-limited colitis that may have been misclassifi ed as IBD) did not change the eff ect estimates. Restricting by both age and fi ve or more claims generated similar results. Restricting the exposure to only subjects with a diagnosis of acne increased the adjusted OR estimates for IBD (OR 1.82, 95 % CI: 1.05, 3.17) and UC (OR 5.63, 95 % CI: 2.41, 13.18), and the association with CD remained nonsignificant ( Table 4 ) . Finally, a diagnosis of acne was not independently associated with UC (OR 1.25, 95 % CI: 0.98, 1.58), CD (OR 0.96, 95 % CI: 0.74, 1.25), or IBD overall (OR 1.11, 95 % CI: 0.94, 1.32), making it unlikely that the relationship between isotretinoin and IBD is confounded by acne.
Sensitivity analysis
We performed a sensitivity analysis to determine how diff erential misclassifi cation of IBD status in isotretinoin exposed and , there are a number of diff erences between this study and ours that may explain the discordant results. Primarily, the median latency time (from the last prescription to the fi rst diagnosis of IBD) was 906 days (range 88 -2,339 days), meaning that a substantial proportion of cases had exposure to isotretinoin 3 -6 years before diagnosis. As temporality is one of the fundamental Bradford -Hill criteria for causation ( 34 ), our study focused on exposures occurring 1 (and 2) years before the fi rst IBD diagnosis. As one would expect with a temporal association, our study found a diminished eff ect when we included those exposures occurring within 2 years before UC diagnosis (OR 2.90), compared with including exposures occurring only within 1 year of diagnosis (OR 4.36) . Th is suggests that the inclusion of exposures occurring many years before diagnosis in the Manitoba study may have biased the results toward the null. Furthermore, our study also analyzed the eff ect of dosage on the association between isotretinoin and IBD, another important causal criterion that was not evaluated in the Manitoba study. Our results suggest that if those on small doses represented a sizeable proportion of the exposed Manitoba population, this could further explain the unexposed individuals might bias our OR estimates. We determined that a positive association between isotretinoin and UC could not be attributed to detection bias, unless the sensitivity of UC diagnosis in the unexposed group was < 50 % (i.e., unless >50 % of IBD cases went undiagnosed in the unexposed groupan unlikely possibility).
DISCUSSION
In this case -control analysis of administrative claims data from a large, commercially insured US population including >8,000 cases of IBD, we found that previous isotretinoin exposure was associated with an increased risk of UC, but not CD. Th ere seemed to be substantial evidence of a " dose -response " relationship for UC. Higher doses of isotretinoin, dose escalation, and longer duration of therapy were all associated with the highest risk of UC. To our knowledge, this is the fi rst epidemiological study to defi ne a positive association between isotretinoin and IBD, and to address important causal criteria, such as strength, temporality, specificity, and dose-related eff ects. Although isolated case reports of IBD developing in isotretinoin users have been previously published, case reports and case CD, Crohn's disease; CI, confi dence interval; IBD, infl ammatory bowel disease; OR, odds ratio; UC, ulcerative colitis. a ORs were determined by conditional logistic regression models, adjusting for age, gender, region, health plan, and length of plan enrollment. INFLAMMATORY BOWEL DISEASE discordant results. Finally, our study contained roughly four times as many IBD cases as the Canadian study, which contributes to the precision and weight of our eff ect estimates.
Our observation of diff erent eff ects for two similar diseases, UC and CD, makes a systematic bias an unlikely explanation for the observed association. Th is fi nding is consistent with other known exposures that diff erentially impact the risk of one, but not both IBDs, including tobacco and previous appendectomy ( 35, 36 ) . Th e biological mechanism by which isotretinoin might lead to UC but not CD is unknown, but is consistent with the understanding that UC and CD have distinct immunological features, and could be related to its eff ects on T-cell function and adaptive immunity, as some have postulated ( 16 ) . Moreover, the consistent fi nding that isotretinoin was associated with ORs < 1 for CD is compelling, given that retinoids are also used in the treatment of psoriasis, a disease process that is immunologically related to CD.
It should be noted that, although the relative risk for UC (estimated in this study by ORs) is high, the absolute risk of UC in subjects treated with isotretinoin is likely quite small. Th e expected number of UC cases in the exposed group (i.e., if the OR was 1.0) would be roughly 4, meaning that 14 " excess " cases were observed within a large population (4,428) of UC patients. Th is low absolute risk should be emphasized when interpreting these results or applying them to patient care decisions. Many patients with disfi guring acne would likely (and do regularly) accept even moderate risks of isotretinoin to ameliorate their condition, as this drug is uniquely effi cacious, especially for severe or recalcitrant acne ( 37, 38 ) .
Our analysis was designed to address some of the potential limitations inherent in using administrative data. First, cases were identifi ed using diagnosis codes rather than clinical records, leading to possible outcome misclassifi cation. To address this, we used administrative defi nitions that were identical or similar to those used previously by our group and others ( 23, 39, 40 ) . Previous studies have validated an administrative claims defi nition of a single IBD ICD-9 diagnosis code, which had a positive predictive value of 81 -84 % and a sensitivity >90 % ( 40 ). We used a more specifi c defi nition ( ≥ 3 IBD diagnoses or ≥ 1 IBD diagnosis + 1 IBD-related prescription) to minimize the possibility of false-positive cases. Furthermore, misclassifying unaff ected individuals as cases and vice versa would underestimate the true exposure -outcome relationship, such that actual risks may be even greater than those reported in this study.
A 1-year period free of claims for IBD may not have been suffi ciently long to exclude all prevalent cases (e.g., cases of mild or quiescent IBD with infrequent claims). To protect against this contamination, we also excluded cases with an IBD-related prescription during the 1-year period. Although residual contamination of incident cases with prevalent cases was still possible, such misclassifi cation would bias our results away from the null only if prevalent cases were more likely than controls to have been treated with isotretinoin, which is unlikely.
It is theoretically possible that isotretinoin is associated with selflimited colitis that was miscoded as UC. To assess this, we used a more stringent defi nition of UC that is unlikely to have included other forms of colitis (fi ve or more coded diagnoses on separate days), and found the strength of the association to be unchanged. Individuals exposed to isotretinoin have greater contact with the health-care system and receive more scrutiny (because of known isotretinoin toxicity and tightly regulated prescribing practices ( 31 )), and hence may be more likely to have their IBD diagnosed and coded than non-isotretinoin users. We performed a sensitivity analysis to address this concern, and determined that detection bias would have to be quite strong (>50 % reduction in detection in unexposed) to nullify the measured positive eff ect.
Th e only opportunity for missing data in an administrative claims database would be encounters for which a claim was not submitted. However, we believe this would be a rare occurrence, given the relatively high cost of both isotretinoin prescriptions and the diagnosis and management of IBD. We measured exposure by prescriptions dispensed, and do not have data regarding adherence and / or discontinuation of therapy. However, given that these are generally highly motivated patients and that in our study, 82 % of subjects had two or more dispensings, we believe that isotretinoin prescribing and actual exposure are closely related. As this study used an insurance claims database, our results may not be generalizable to uninsured populations, although we have no reason to suspect that the biological eff ects of isotretinoin would diff er based on insurance status.
We did not assess the use of antibiotics preceding exposure to isotretinoin. Previous studies have suggested either no association or a small positive association between previous antibiotic exposure and the development of IBD; however, most of the literature is related to CD not UC ( 41 -43 ) . Th erefore, we do not believe that antibiotic use is likely to be a signifi cant confounder of the relationship between isotretinoin and UC.
Finally, it is important to note that some dermatological conditions such as pyoderma faciale may be extraintestinal manifestations of IBD. If isotretinoin was prescribed for such conditions in our study population, it would potentially bias our results away from the null. However, >90 % of isotretinoin users (and 100 % of exposed cases) had a diagnosis of acne vulgaris, suggesting that isotretinoin use for these rare cutaneous manifestations of IBD is uncommon. Furthermore, restricting the exposure defi nition to subjects with a diagnosis of acne in conjunction with isotretinoin did not alter our estimates. Although some have speculated an association between acne itself and IBD ( 44 ), in our study, a diagnosis of acne was not independently associated with either UC or CD, and adjustment for acne in multivariate analysis did not substantially alter our OR estimates or their statistical signifi cance.
In conclusion, this case -control study demonstrates a possible causal association between isotretinoin use and UC, but not CD. Temporality, eff ect specifi city, and increasing eff ects for both intensity and duration of therapy provide further evidence of causation. As this is the fi rst epidemiological study to describe a positive association between isotretinoin and UC, these results should be confi rmed by additional studies in other populations. Although the absolute risk of developing IBD aft er taking isotretinoin is likely quite small, clinicians prescribing isotretinoin as well as prospective patients should be aware of this possible association.
